WEST

Generate Collection | Print

Search Results - Record(s) 1 through 1 of 1 returned.

☐ 1. Document ID: US 20030022892 A1

L1: Entry 1 of 1 File: PGPB Jan 30, 2003

PGPUB-DOCUMENT-NUMBER: 20030022892
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030022892 A1

TITLE: Methods for treating cognitive/attention deficit disorders using tetrahydroindolone analogues and derivatives

PUBLICATION-DATE: January 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Glasky, Alvin J.	Mission Vieso	CA	US	
Fick, David B.	Tustin	CA	US	
Helton, David	Irvine	CA	US	

US-CL-CURRENT: 514/227.8; 514/232.8, 514/254.09, 514/323, 514/365, 514/374, 514/397, 514/415

Full | Title | CIT.1 [redacted] REV.1 CLS.1 [redacted] REF.1 SEQ.1 ATT.1 [redacted] KWC.1

Generate Collection | Print

Terms	Documents
20030022892	1

Display Format: CIT | Change Format

Previous Page Next Page

Welcome to STN International! Enter x:x

LOGINID:ssspta1611sxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Apr 08	"Ask CAS" for self-help around the clock
NEWS 3	Jun 03	New e-mail delivery for search results now available
NEWS 4	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 5	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS 6	Aug 26	Sequence searching in REGISTRY enhanced
NEWS 7	Sep 03	JAPIO has been reloaded and enhanced
NEWS 8	Sep 16	Experimental properties added to the REGISTRY file
NEWS 9	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS 10	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS 11	Oct 24	BEILSTEIN adds new search fields
NEWS 12	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 13	Nov 18	DKILIT has been renamed APOLLIT
NEWS 14	Nov 25	More calculated properties added to REGISTRY
NEWS 15	Dec 04	CSA files on STN
NEWS 16	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 17	Dec 17	TOXCENTER enhanced with additional content
NEWS 18	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS 19	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS 20	Feb 13	CANCERLIT is no longer being updated
NEWS 21	Feb 24	METADEX enhancements
NEWS 22	Feb 24	PCTGEN now available on STN
NEWS 23	Feb 24	TEMA now available on STN
NEWS 24	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS 25	Feb 26	PCTFULL now contains images
NEWS 26	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 27	Mar 20	EVENTLINE will be removed from STN
NEWS 28	Mar 24	PATDPAFULL now available on STN
NEWS 29	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS 30	Apr 11	Display formats in DGENE enhanced
NEWS 31	Apr 14	MEDLINE Reload
NEWS 32	Apr 17	Polymer searching in REGISTRY enhanced
NEWS 33	Apr 21	Indexing from 1947 to 1956 being added to records in CA/CAPLUS
NEWS 34	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS 35	Apr 28	RDISCLOSURE now available on STN
NEWS 36	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS 37	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS 38	May 15	Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS 39	May 16	CHEMREACT will be removed from STN

NEWS 40 May 19 Simultaneous left and right truncation added to WSCA
NEWS 41 May 19 RAPRA enhanced with new search field, simultaneous left and right truncation

NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 07:39:22 ON 24 MAY 2003

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 07:39:29 ON 24 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 22 MAY 2003 HIGHEST RN 519137-84-9
DICTIONARY FILE UPDATES: 22 MAY 2003 HIGHEST RN 519137-84-9

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 09839289.1

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 H,Et

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 07:39:55 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1 TO ITERATE

100.0% PROCESSED 1 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1 TO 80
PROJECTED ANSWERS: 1 TO 80

L2 1 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 07:40:02 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 20 TO ITERATE

100.0% PROCESSED 20 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

L3 2 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION

FULL ESTIMATED COST 148.15 148.36

FILE 'CAPLUS' ENTERED AT 07:40:09 ON 24 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 24 May 2003 VOL 138 ISS 22
FILE LAST UPDATED: 23 May 2003 (20030523/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 7 L3

=> d l4 fbib hitstr abs total

L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2003 ACS
AN 2003:77551 CAPLUS
DN 138:131150
TI Methods for treating cognitive/attention deficit disorders using tetrahydroindolone analogues and derivatives
IN Glasky, Alvin J.; Fick, David B.; Helton, David
PA USA
SO U.S. Pat. Appl. Publ., 15 pp., Cont.-in-part of U. S. Ser. No. 839,289.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003022892	A1	20030130	US 2002-193550	20020709
				US 2001-839289 A2	20010420
	US 2002198218	A1	20021226	US 2001-839289	20010420

PATENT FAMILY INFORMATION:
FAN 2002:832760

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002085856	A1	20021031	WO 2002-US11142	20020408

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,

UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2001-839289 A 20010420
US 2002198218 A1 20021226 US 2001-839289 20010420
OS MARPAT 138:131150
IT **389799-42-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(and metabolites; treating cognitive/attention deficit disorders using tetrahydroindolone analogs and derivs.)
RN 389799-42-2 CAPLUS
CN Benzoic acid, 4-[[1-oxo-3-(4,5,6,7-tetrahydro-4-oxo-1H-indol-1-yl)propyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



AB Methods for treating cognitive/attention deficit disorders in general using tetrahydroindolone derivs. and analogs, particularly tetrahydroindolone derivs. or analogs in which the tetrahydroindolone deriv. or analog is covalently linked to another moiety to form a bifunctional conjugate are disclosed. More specifically, methods and compns. for treating attention deficit disorder and attention deficit hyperactivity disorders in adults and children as well as mild cognitive impairment and dementia are provided.

L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2003 ACS
AN 2002:832760 CAPLUS
DN 137:337779
TI Preparation of tetrahydroindolone analogs and derivatives as nootropic agents
IN Fick, David B.; Foreman, Mark M.; Glasky, Alvin J.
PA Neotherapeutics, Inc., USA
SO PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002085856	A1	20021031	WO 2002-US11142	20020408

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,

TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2001-839289 A 20010420
US 2002198218 A1 20021226 US 2001-839289 20010420

PATENT FAMILY INFORMATION:

FAN 2003:77551

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003022892	A1	20030130	US 2002-193550	20020709
				US 2001-839289 A2	20010420
	US 2002198218	A1	20021226	US 2001-839289	20010420

OS MARPAT 137:337779

IT **389799-42-2P 389799-43-3P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of tetrahydroindolone analogs and derivs. as nootropic agents)

RN 389799-42-2 CAPLUS
CN Benzoic acid, 4-[[1-oxo-3-(4,5,6,7-tetrahydro-4-oxo-1H-indol-1-yl)propyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 389799-43-3 CAPLUS
CN Benzoic acid, 4-[[1-oxo-3-(4,5,6,7-tetrahydro-4-oxo-1H-indol-1-yl)propyl]amino]- (9CI) (CA INDEX NAME)



GI



I

AB Tetrahydroindolone analogs and derivs. (e.g., I; wherein R = H, Et) were prepd. Compd. I (R = Et) was prepd. in 56% yield by reacting acryloyl chloride with 4-aminobenzoic acid Et ester to give 76% 4-acryloylaminobenzoic acid Et ester, followed by reaction with 1,5,6,7-tetrahydro-4H-indol-4-one. Compd. I (R = H) is then accessed through hydrolysis of the product. The prepd. compds. showed good activity as nootropic agents. Thus, the minimal ED of I (R = Et) was 0.001 mg/kg in a passive avoidance test on mice.

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2003 ACS
AN 2002:51464 CAPLUS
DN 136:112673
TI Methods using a purine derivative, pyrimidine derivative, or tetrahydroindolone derivative for treatment of disease-induced peripheral neuropathy and related conditions
IN Diamond, Jack; Glasky, Alvin J.
PA Neotherapeutics, Inc., USA
SO PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002004452	A2	20020117	WO 2001-US21526	20010706
	WO 2002004452	A3	20030103		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2002055506	A1	20020509	US 2000-216844PP	20000707
			US 2001-900844	20010706
US 2002061899	A1	20020523	US 2000-216844PP	20000707
			US 2001-899901	20010706
			US 2000-216844PP	20000707

PATENT FAMILY INFORMATION:

FAN 2002:51460

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002004448	A2	20020117	WO 2001-US21373	20010706
WO 2002004448	A3	20030123		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

			US 2000-216844PP	20000707
US 2002055506	A1	20020509	US 2001-900844	20010706
			US 2000-216844PP	20000707
US 2002061899	A1	20020523	US 2001-899901	20010706
			US 2000-216844PP	20000707

OS MARPAT 136:112673

IT **389799-42-2 389799-43-3**

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(purine derivs., pyrimidine derivs., and tetrahydroindolone derivs. for treatment of disease-induced peripheral neuropathy and related conditions)

RN 389799-42-2 CAPLUS

CN Benzoic acid, 4-[[1-oxo-3-(4,5,6,7-tetrahydro-4-oxo-1H-indol-1-yl)propyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 389799-43-3 CAPLUS

CN Benzoic acid, 4-[[1-oxo-3-(4,5,6,7-tetrahydro-4-oxo-1H-indol-1-yl)propyl]amino]- (9CI) (CA INDEX NAME)



AB A method of treating disease-induced peripheral neuropathy comprises administering to a patient with disease-induced peripheral neuropathy an effective quantity of a purine deriv. or analog, a tetrahydroindolone deriv. or analog, or a pyrimidine deriv. or analog. If the compd. is a purine deriv., the purine moiety can be guanine or hypoxanthine. The compd. can induce peripheral nerve sprouting through the action of a

neurotrophic factor such as nerve growth factor (NGF) without the occurrence of hyperalgesia. The peripheral nerve sprouting can be nociceptive nerve sprouting. The disease-induced peripheral neuropathy can be diabetic neuropathy or disease-induced peripheral neuropathy with another basis.

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2003 ACS
AN 2002:51463 CAPLUS
DN 136:112672
TI Methods using a purine derivative,pyrimidine derivative, or tetrahydroindolone derivative for stimulation of synthesis of synaptophysin in the central nervous system
IN Glasky, Michelle; Lahiri, Debomoy K.; Farlow, Martin R.
PA Neotherapeutics, Inc., USA
SO PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002004451	A2	20020117	WO 2001-US21385	20010706
	WO 2002004451	A3	20030103		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				US 2000-216808PP	20000707
	US 2002040032	A1	20020404	US 2001-899478	20010705
				US 2000-216808PP	20000707

OS MARPAT 136:112672
IT **389799-42-2 389799-43-3**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(purine deriv.,pyrimidine deriv., or tetrahydroindolone deriv. for stimulation of synthesis of synaptophysin in CNS)
RN 389799-42-2 CAPLUS
CN Benzoic acid, 4-[[1-oxo-3-(4,5,6,7-tetrahydro-4-oxo-1H-indol-1-yl)propyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 389799-43-3 CAPLUS
CN Benzoic acid, 4-[[1-oxo-3-(4,5,6,7-tetrahydro-4-oxo-1H-indol-1-yl)propyl]amino]- (9CI) (CA INDEX NAME)



AB A method of increasing the synthesis and/or secretion of synaptphysin comprises administering to a patient with a neurol. disease or a patient at risk of developing a neurol. disease an effective quantity of a purine deriv. of analog, a tetrahydroindolone deriv. or analog, or a pyrimidine deriv. or analog. If the compd. is a purine deriv., the purine moiety can be guanine or hypoxanthine. The neurol. disease can be a neurodegenerative disease such as Alzheimer's disease or a neurodevelopmental disorder such as Down's syndrome. Typically, the compd. can pass through the blood-brain barrier. A particularly preferred purine deriv. is N-4-carboxyphenyl-3-(6-oxohydropurin-9-yl)propanamide.

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2003 ACS
AN 2002:51462 CAPLUS
DN 136:112671
TI Methods using a purine derivative, pyrimidine derivative, or tetrahydroindolone derivative for prevention of accumulation of amyloid .beta. peptide in the central nervous system
IN Glasky, Michelle; Lahiri, Debomoy K.; Farlow, Martin R.
PA Neotherapeutics, Inc., USA
SO PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002004450	A2	20020117	WO 2001-US21384	20010706
WO 2002004450	A3	20021212		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

			US 2000-216845PP	20000707
US 2002040031	A1	20020404	US 2001-899611	20010705
			US 2000-216845PP	20000707

OS MARPAT 136:112671
IT **389799-42-2 389799-43-3**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(purine deriv., pyrimidine deriv., or tetrahydroindolone deriv. for prevention of accumulation of amyloid .beta. peptide in CNS)
RN 389799-42-2 CAPLUS
CN Benzoic acid, 4-[[1-oxo-3-(4,5,6,7-tetrahydro-4-oxo-1H-indol-1-

yl)propyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 389799-43-3 CAPLUS
CN Benzoic acid, 4-[[1-oxo-3-(4,5,6,7-tetrahydro-4-oxo-1H-indol-1-yl)propyl]amino]- (9CI) (CA INDEX NAME)



AB A method of either inhibiting the formation of A.beta. or stimulating the formation of sAPP comprises administering to a patient with a neurol. disease or a patient at risk of developing a neurol. disease an effective quantity of a purine deriv. or analog, a tetrahydroindolone deriv. or analog, or a pyrimidine deriv. or analog. If the compd. is a purine deriv., the purine moiety can be guanine or hypoxanthine. The neurol. disease can be a neurodegenerative disease such as Alzheimer's disease or a neurodevelopmental disorder such as Down's syndrome. Typically, the compd. can pass through the blood-brain barrier. A particularly preferred purine deriv. is N-4- carboxyphenyl-3-(6-oxohydropurin-9-yl)propanamide.

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2003 ACS
AN 2002:51461 CAPLUS
DN 136:112691
TI Methods using a purine derivative, a pyrimidine derivative or a tetrahydroindolone derivative for treatment of conditions affected by activity of multidrug transporters
IN Taylor, Eve M.
PA Neotherapeutics, Inc., USA
SO PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002004449	A2	20020117	WO 2001-US21383	20010706
	WO 2002004449	A3	20020613		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2002128264 A1 20020912 US 2000-216616PP 20000707
US 2001-900297 20010706
US 2000-216616PP 20000707

OS MARPAT 136:112691

IT **389799-42-2 389799-43-3**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(purine deriv., pyrimidine deriv. or tetrahydroindolone deriv. for treatment of conditions affected by activity of multidrug transporters)

RN 389799-42-2 CAPLUS
CN Benzoic acid, 4-[[1-oxo-3-(4,5,6,7-tetrahydro-4-oxo-1H-indol-1-yl)propyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 389799-43-3 CAPLUS
CN Benzoic acid, 4-[[1-oxo-3-(4,5,6,7-tetrahydro-4-oxo-1H-indol-1-yl)propyl]amino]- (9CI) (CA INDEX NAME)



AB One aspect of the invention is a method of treating a condition or disease assocd. with the activity of a multidrug transporter protein comprising administering to a mammal with a condition or disease assocd. with the activity of a multidrug transporter protein an effective quantity of a purine deriv. or analog, a tetrahydroindolone deriv. or analog, or a pyrimidine deriv. or analog. If the compd. is a purine deriv., the purine moiety can be guanine or hypoxanthine. A particularly preferred bifunctional purine deriv. is N-4-carboxyphenyl-3-(6-oxohydropurin-9-yl)propanamide. The methods of the invention can be used to treat cancer, a microbial or parasitic infection, HIV, infection, or a condition assocd. with inflammation, e.g. asthma or rheumatic disease.

L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2003 ACS
AN 2002:51460 CAPLUS
DN 136:112670
TI Methods using purine derivatives, pyrimidine derivatives, and tetrahydroindolone derivatives for treatment of drug-induced peripheral neuropathy and related conditions
IN Diamond, Jack; Glasky, Alvin J.
PA Neotherapeutics, Inc., USA

SO PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002004448	A2	20020117	WO 2001-US21373	20010706
	WO 2002004448	A3	20030123		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				US 2000-216844PP	20000707
	US 2002055506	A1	20020509	US 2001-900844	20010706
				US 2000-216844PP	20000707
	US 2002061899	A1	20020523	US 2001-899901	20010706
				US 2000-216844PP	20000707

PATENT FAMILY INFORMATION:
FAN 2002:51464

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002004452	A2	20020117	WO 2001-US21526	20010706
	WO 2002004452	A3	20030103		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				US 2000-216844PP	20000707
	US 2002055506	A1	20020509	US 2001-900844	20010706
				US 2000-216844PP	20000707
	US 2002061899	A1	20020523	US 2001-899901	20010706
				US 2000-216844PP	20000707

OS MARPAT 136:112670
IT **389799-42-2 389799-43-3**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(purine derivs., pyrimidine derivs., and tetrahydroindolone derivs. for treatment of drug-induced peripheral neuropathy and related conditions)
RN 389799-42-2 CAPLUS
CN Benzoic acid, 4-[[1-oxo-3-(4,5,6,7-tetrahydro-4-oxo-1H-indol-1-yl)propyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 389799-43-3 CAPLUS
CN Benzoic acid, 4-[[1-oxo-3-(4,5,6,7-tetrahydro-4-oxo-1H-indol-1-yl)propyl]amino]- (9CI) (CA INDEX NAME)



AB A method of treating drug-induced peripheral neuropathy comprises administering to a patient with drug-induced peripheral neuropathy an effective quantity of a purine deriv. or analog, a tetrahydroindolone deriv. or analog, or a pyrimidine deriv. or analog. If the compd. is a purine deriv., the purine moiety can be guanine or hypoxanthine. The compd. can induce peripheral nerve sprouting through the action of a neurotrophic factor such as nerve growth factor (NGF) without the occurrence of hyperalgesia. The peripheral nerve sprouting can be nociceptive nerve sprouting. The drug-induced peripheral neuropathy can be drug-induced peripheral neuropathy assocd. with the administration of oncolytic drugs, such as a vinca alkaloid, cisplatin, paclitaxel, suramin, altretamine, carboplatin, chlorambucil, cytarabine, dacarbazine, docetaxel, etoposide, fludarabine, ifosfamide with mesna, tamoxifen, teniposide, or thioguanine. The methods of the invention are particularly useful in treating peripheral neuropathy assocd. with the administration of vincristine, paclitaxel, or cisplatin.

=> d cost

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
CONNECT CHARGES	0.34	0.83
NETWORK CHARGES	0.06	0.18
SEARCH CHARGES	0.00	147.75
DISPLAY CHARGES	53.24	53.24
	53.64	202.00
CAPLUS FEE (5%)	2.68	2.68
FULL ESTIMATED COST	56.32	204.68

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-4.56	-4.56

IN FILE 'CAPLUS' AT 07:40:42 ON 24 MAY 2003

```
=> d his

     (FILE 'HOME' ENTERED AT 07:39:22 ON 24 MAY 2003)

     FILE 'REGISTRY' ENTERED AT 07:39:29 ON 24 MAY 2003
L1                STRUCTURE UPLOADED
L2              1 S L1
L3              2 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 07:40:09 ON 24 MAY 2003
L4              7 S L3
```